JP2023505441A5 - - Google Patents

Info

Publication number
JP2023505441A5
JP2023505441A5 JP2022532697A JP2022532697A JP2023505441A5 JP 2023505441 A5 JP2023505441 A5 JP 2023505441A5 JP 2022532697 A JP2022532697 A JP 2022532697A JP 2022532697 A JP2022532697 A JP 2022532697A JP 2023505441 A5 JP2023505441 A5 JP 2023505441A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
group
functional
fatty acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022532697A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023505441A (ja
JP7788376B2 (ja
Filing date
Publication date
Priority claimed from PCT/EP2019/083506 external-priority patent/WO2020115048A1/en
Application filed filed Critical
Priority claimed from PCT/EP2020/084487 external-priority patent/WO2021110845A1/en
Publication of JP2023505441A publication Critical patent/JP2023505441A/ja
Publication of JP2023505441A5 publication Critical patent/JP2023505441A5/ja
Priority to JP2025141835A priority Critical patent/JP2025172864A/ja
Application granted granted Critical
Publication of JP7788376B2 publication Critical patent/JP7788376B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022532697A 2019-12-03 2020-12-03 最適化されたgipペプチド類縁体 Active JP7788376B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025141835A JP2025172864A (ja) 2019-12-03 2025-08-28 最適化されたgipペプチド類縁体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EPPCT/EP2019/083506 2019-12-03
PCT/EP2019/083506 WO2020115048A1 (en) 2018-12-03 2019-12-03 Modified gip peptide analogues
EP20179259 2020-06-10
EP20179259.5 2020-06-10
PCT/EP2020/084487 WO2021110845A1 (en) 2019-12-03 2020-12-03 Optimized gip peptide analogues

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025141835A Division JP2025172864A (ja) 2019-12-03 2025-08-28 最適化されたgipペプチド類縁体

Publications (3)

Publication Number Publication Date
JP2023505441A JP2023505441A (ja) 2023-02-09
JP2023505441A5 true JP2023505441A5 (cg-RX-API-DMAC7.html) 2023-12-12
JP7788376B2 JP7788376B2 (ja) 2025-12-18

Family

ID=71083547

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022532697A Active JP7788376B2 (ja) 2019-12-03 2020-12-03 最適化されたgipペプチド類縁体
JP2025141835A Pending JP2025172864A (ja) 2019-12-03 2025-08-28 最適化されたgipペプチド類縁体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025141835A Pending JP2025172864A (ja) 2019-12-03 2025-08-28 最適化されたgipペプチド類縁体

Country Status (10)

Country Link
US (1) US20250346647A2 (cg-RX-API-DMAC7.html)
EP (1) EP4069719A1 (cg-RX-API-DMAC7.html)
JP (2) JP7788376B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220108064A (cg-RX-API-DMAC7.html)
CN (2) CN122520749A (cg-RX-API-DMAC7.html)
AU (1) AU2020398675A1 (cg-RX-API-DMAC7.html)
CA (1) CA3157387A1 (cg-RX-API-DMAC7.html)
IL (1) IL293249A (cg-RX-API-DMAC7.html)
MX (1) MX2022006737A (cg-RX-API-DMAC7.html)
WO (1) WO2021110845A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023014740A (es) * 2021-06-10 2024-03-13 Antag Therapeutics Aps Tratamiento de la obesidad y trastornos relacionados con la obesidad.
WO2023139106A2 (en) * 2022-01-18 2023-07-27 Novo Nordisk A/S Long-acting gipr antagonists
CN117402219B (zh) 2022-07-13 2024-07-30 杭州中美华东制药有限公司 Glp-1/gip双激动剂及其制备方法和用途
AR134436A1 (es) * 2023-11-22 2026-01-14 Hangzhou Zhongmeihuadong Pharmaceutical Co Ltd Uso de un agonista dual glp-1r / gipr en la fabricación de un medicamento veterinario
TW202615088A (zh) * 2024-06-14 2026-04-16 美商美國禮來大藥廠 用於改善胰島素敏感性之組合物及方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101155828A (zh) * 2005-02-11 2008-04-02 安米林药品公司 Gip类似物和具有可选择性质的杂合多肽
US8263545B2 (en) * 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
CA2597649A1 (en) * 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Inc. Gip analog and hybrid polypeptides with selectable properties
JP5399244B2 (ja) * 2006-08-17 2014-01-29 アミリン・ファーマシューティカルズ,リミテッド・ライアビリティ・カンパニー 選択可能な特性を持つdpp−iv耐性gipハイブリッドポリペプチド
CA2732949C (en) * 2008-08-07 2016-12-20 Ipsen Pharma S.A.S. Analogues of glucose-dependent insulinotropic polypeptide
ES2574835T3 (es) * 2008-08-07 2016-06-22 Ipsen Pharma S.A.S. Análogos del polipéptido insulinotrópico dependiente de glucosa
WO2010016936A1 (en) * 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Pharmaceutical compositions of analogues of glucose-dependent insulinotropic polypeptide
CN103003300B (zh) * 2010-04-27 2017-06-09 西兰制药公司 Glp‑1受体激动剂和胃泌素的肽缀合物及其用途
CA2872314C (en) * 2012-05-03 2021-08-31 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
WO2016034186A1 (en) 2014-09-05 2016-03-10 University Of Copenhagen Gip peptide analogues
US11572399B2 (en) * 2017-05-31 2023-02-07 University Of Copenhagen Long-acting GIP peptide analogues
TWI912614B (zh) * 2017-12-21 2026-01-21 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
US12187773B2 (en) * 2018-12-03 2025-01-07 Antag Therapeutics Aps Modified GIP peptide analogues

Similar Documents

Publication Publication Date Title
JP2022509568A5 (cg-RX-API-DMAC7.html)
JP7658877B2 (ja) インクレチン類似体およびその使用
JP7605747B2 (ja) 修飾されたgipペプチド類似体
CN103596583B (zh) 新型胰高血糖素类似物
JP2025172864A5 (cg-RX-API-DMAC7.html)
JP6054742B2 (ja) アシル化グルカゴン類似体
JP5635529B2 (ja) グルカゴン類似体
JP5524049B2 (ja) 目的ペプチドの血漿中半減期延長作用を有するペプチド
JP7443315B2 (ja) アシル化オキシントモジュリンペプチド類似体
JP2011502159A5 (cg-RX-API-DMAC7.html)
JP2024521398A5 (cg-RX-API-DMAC7.html)
TW201716431A (zh) 升糖素及glp-1共激動劑化合物
CN119119235A (zh) 酰化胰高血糖素类似物
AU2011206979A1 (en) Treatment of cardiac conditions
KR20110040760A (ko) 대사 질환 및 비만 치료용 gip-기초된 혼합형 항진제
CN108271356A (zh) 肠降血糖素-胰岛素缀合物
JP2012506402A5 (cg-RX-API-DMAC7.html)
CA2931694C (en) Fatty acid derivatives of dimeric peptide ligands of psd-95 and use thereof for treating excitotoxic disease
JP2020521784A5 (cg-RX-API-DMAC7.html)
JP7440663B2 (ja) 長時間作用型glp-1およびグルカゴン受容体デュアルアゴニスト
EP2293811A1 (en) Derivatised hybrid peptides of amylin and salmon calcitonin
EP4547703A1 (en) Amylin receptor (hamy3r) agonists with improved chemical stability
EA050089B1 (ru) Полипептиды и варианты их применения
JP6006264B2 (ja) グルカゴン類似体
RU2024100299A (ru) Лечение ожирения и связанных с ожирением нарушений